The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
up 18% and going much higher
This is like a coiled spring I feel there is a buyer mopping them up at this level - The market is aware of the potential upside
Got go go much higher. Double bagger now. Strong opening and continual rise upwards of 8 pence.
Good luck to everyone invested in IMM, lets see what today brings, I have a feeling it may be interesting!
Frits
Well the same google finance shows the price going from 22p to 170p during the last phase 3 trial of Lupozor and a £250m mcap… currently at £10m mcap with two phase 2/3 trials now at the FDA approval stage targeting multi billion $ markets. Opportunity knocks from the companies with the lowest valuations and the highest blue sky potential, the fact Avion we’re happy to put £1.1m in at 11p shows the value they see in IMM. Warrants kick in at 5p, something tells me 5p will be hit and soon given L1 and Lind warrants expire 10th June they will want the price above 5p before they expire imo, TGI’s company has a habit or re rating once momentum is with it, we are right at the beginning of the upward curve imo
Scored againsteps,
The U turn was necessary and things seem to be going in the right direction for a change :)
However as usual one has to be aware of the pot holes with IMM and be reactive …
P.s. keep your eyes on the warrants and not on the sky :-)
The spread on this is 11%. A quick look at the sp history on Google finance for the last 5 years explains why. In my opinion- steer clear.
Alongside the blockbuster potential of Lupozor for Lupus and the CIDP trials both of which target multi billion $ markets we also have the recently announced partnership with Orano which does look particularly exciting.
Key points:
· Orano has paid a small undisclosed amount to ImmuPharma for a 12-month collaboration to identify suitable radiotherapy candidates for the treatment of cancer.
· ImmuPharma has agreed to provide its peptide technology, to explore the potential to allow delivery of a potent radioactive isotope to the core of a cancer cell.
· Our team based in Bordeaux, (ImmuPharma Biotech), in conjunction with Orano and the Cancer Research Centre of Lyon (CRCL), will work together to identify molecules that can carry the radioactive entity.
· Any potential new cancer therapeutic using ImmuPharma's peptide technology, discovered as part of the collaboration will be subject to a full licensing agreement between ImmuPharma and Orano in preparation for further development by Orano.
· The therapeutic goal is to use ImmuPharma's peptide technology to deliver a radioactive bullet to the nucleus of cancer cells, killing the cell with minimal impact on surrounding tissue.
· The radiopharmaceuticals market is expected to achieve global sales *€8.5bn by 2031. The combination of ImmuPharma's peptide technology and a powerful radioactive bullet is an exciting new approach with significant commercial potential.
....near to cut even so mist wait and hope its not a pump'n dump. But I have had patience with many other specs and sometimes they can work out. Staying put and hoping!
Score
Immupharma is up 70% in past 5 days admittedly from a very low SP but it does suggest a serious rerating is occurring .
It doesn't look like a one day pump and dump but with Immupharma you never know.
Tomorrow will tell all imho
ATB to long suffering investors here
Nice to see Imm rise will look in morning gl
I also fully agree with the posts this weekend, your points and comments are all very well put. I would lean more toward there not being a takeover at this stage. For a Big Pharma to lay out a load of cash on a product that is not yet proven by data is unlikely but not out of the realms of probability.
Personally, I would rather see some internal growth from within IMM and allow the products to speak for themselves, P140 already has a very bright future as does Lupuzor. I am however confident of a rise in the price of IMM. I too have been here for as long as Dallo, while I certainly dont hold the same number of shares which is Impressive to say the least, I still hold a considerable amount. But in all honesty, over the years, nothing now surprises me with IMM.
As most of you know, I am a very strong believer in the science behind P140. Its not just CIDP or Lupus that P140 may be able to manage, there is a whole host autoimmune diseases that could potentially be targeted by this mode of action.
I for one am very confident regards the future of IMM, but then I always have been which is why I have remained an investor in this company.
Enjoy the remainder of your weekend.
Frits
well said everyone, and i think we are all in at the right place at the right time.
on the right horse, which is very hard to find in these savage Market,
but as POKER SAY'' I too don't think it's the right time for the CO to entertain a BID
so close to a possible FDA approval
but whisper of a bid at some point would certainly put a rocket under under
this price we are ATM, or whatever it is next week
we will see how it plays out
but it's really nice to see some rational post with reasoning
ATB
I do not see this as a takeover target at present ...... it is very difficult to value a company like this in the middle of potential trials ..so it is very difficult to put forward a reasonable offer price.... anyone interested would no doubt wait for the trial results and are unlikely to take the risk of having to pay a high takeover price at this stage, before such results are known...big pharma would be more likely to play fair and pay on the trial result value IMO
The only bids at this stage IMO would be where the company itself found it necessary to have a strategic review and put itself up for sale ...but I don't see that happening ...
IMO the more likely next step might be that there "could" be a private placing from a new external investor wanting to take a stake and offering to inject some cash via a private placing to support the ongoing developments.....but clearly existing shareholders would need to be supportive of such a move in order to balance their own voting rights and positions
I am really looking forward to next week as it really looks like the MMs were struggling to keep a lid on the move upwards, as there was so much demand for the stock. Like so many on here have started to appreciate the actual value of what was announced and have started to read between the lines of what is going on. £10m market cap is ridiculously low and to me that makes Immupharma a walking TO target - we will no doubt see more on this next week, but expect the bid on the sp to be strong come Monday.
If the FDA approves the Phase 2/3 trials for both Lupuzor and CIPD , allied to a rest of the world deal on Lupuzor with a large ( French??) Pharma plus a deal on funding with CIPD with another player or more likely a full bid for Immupharma then we MAY be heading for some serious drama and a major increase in the SP over the next few weeks.
We shall know a lot more on Monday if the SP heads further north.
Wishful thinking, I know, but something is afoot imho.
so i suppose we are still at 3.15p if it wasn't for the UT trade at the end of play
that is giving the wrong impression ATM with the 2.95p shown bid 2.96 ask 3.28
what a FKN good move north, from 2 weeks ago prices
and one would expect to see 5p+ for the next level, as it has certainly
pass all my expectation of 3.20p in a few days, in 6 hours,
what will it do next week, if Avion news drop?
I wouldn't want to speculate, but directors did buy at 8p to 11p
could be a possibility ?
lets not forget how fast this can move, with only 300m in issue
and mostly tightly held, and we have been warned about IMM
been significantly undervalued, over the last 3 months
I'm really looking forward to next week more than ever and to this stock hitting
higher highs and higher lows, until we get FDA approval
ATB
...I can see stake-building in preparation for a takeover battle. They still have a fair way to go before I am at the surface let alone making money!
Alora and Immupharma playing the patient game with the FDA on Lupuzor and now independently going for CIPD Phase 2/3 trials is a game changer imho.
Maybe old Tim will finally get the biggest win of his life.
A market cap of £9/10 m now seems ridiculous.
The price action today suggests a leak..expect some serious news on Monday.
I still hold 2.5m shares at 16p and you never know after 8 years I may be rewarded for my stubbornness.
Here's hoping
ATB
It has to be said guys.
I certainly would not want to be out of this over the weekend ; )
Such a strong buy, one of the most under valued stocks out there.
Have good weekend all you that have some skin in this game.
Frits
@ lordloadsoflolly: you we saying??? Ramper?
I stand by my previous post (below). Good luck to all long term investors!
P140 clinical programThu 15:52
The recent RNS from ImmuPharma has brought some truly exciting news regarding P140 clinical program for chronic idiopathic demyelinating polyneuropathy (CIDP). Immupharma has secured a pre-IND meeting date with the FDA for the Phase 2/3 adaptive study of P140 in CIDP, marking a game-changing milestone as it will be the first pivotal clinical study of P140 in patients with this rare neurological disease.
What's even more thrilling is that following the pre-IND meeting, Immupharma plans to submit an application for Orphan Drug status. If approved, Immupharma will enjoy 7 years of market exclusivity post-marketing approval, giving Immupharma a significant edge in the CIDP market. And here's the icing on the cake: the CIDP market is projected to reach a staggering US$2.7 billion in global sales by 2029, showcasing the immense potential of P140 in this space.
To shed some light on the difference between Lupuzor and P140: Lupuzor is a specific formulation of the P140 peptide that Immupharma has developed for treating systemic lupus erythematosus (SLE). On the other hand, P140 is a versatile platform with the potential to address various autoimmune and inflammatory conditions, including CIDP. Both Lupuzor and P140 share a groundbreaking mechanism of action that selectively corrects the biological mechanisms responsible for autoimmune and inflammatory conditions.
In a nutshell, the recent announcement by Immupharma regarding the P140 clinical program for CIDP is nothing short of exhilarating! With the potential revenue from the booming CIDP market and the pursuit of Orphan Drug status, the value of investments in Immupharma could soar to new heights. I look forward to hearing more updates on this promising development, as it could have a massive impact on the lives of CIDP patients and the growth of investments in this domain.
Disclaimer: This note is for informational purposes only and should not be construed as financial advice. Please consult a professional financial advisor before making any investment decisions.
watching ,waiting to buy above shelf
https://invst.ly/-s2sp
best Friday we have ever had, in a long long while IMO
a very long AU without PME at the end closed with a glitch UT 2.95P
next week will be interesting''
good weekend
High finish for the day tee’d up nicely for next week
Sellers will probably regret their choice next week - big order filling or news has been leaked